Teva, Alvotech Secure Eylea Biosimilar Launch Date via Settlement
Event summary
- Alvotech and Teva have reached a settlement with Regeneron regarding the U.S. launch of AVT06, a biosimilar to Eylea® (aflibercept).
- The settlement allows for marketing of AVT06 in the U.S. in Q4 2026, with potential for earlier launch.
- AVT06 has already received marketing approval in Japan, Europe, and the UK.
- Clinical trial data released in 2025 demonstrated high similarity between AVT06 and Eylea®.
The big picture
This settlement represents a significant step for both Alvotech and Teva, allowing them to enter the lucrative U.S. market for Eylea® biosimilars. The agreement mitigates the risk of protracted patent litigation, a common hurdle for biosimilar developers. The success of AVT06 will be a key indicator of Teva’s broader strategy to revitalize its business through biosimilar development and commercialization, particularly given its ongoing restructuring and focus on innovative biopharmaceuticals.
What we're watching
- Regulatory Risk
- The FDA approval process remains a critical uncertainty; any delays or requests for additional data could push back the launch date and impact Teva's projections.
- Competitive Landscape
- The biosimilar market for Eylea® is expected to be highly competitive, and Teva's success will depend on its ability to effectively price and distribute AVT06 against other entrants.
- Commercial Execution
- Teva's ability to successfully integrate Alvotech’s biosimilar and achieve anticipated market penetration will be key to realizing the financial benefits of this settlement.
Related topics